Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
NCT03289039 · Dana-Farber Cancer Institute · PHASE2 · terminated · last registry update 2026-01-22 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual” | – | Registry record, Dana-Farber Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-02-12Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Doxorubicin (NCT03101748)
- 2026-02-12Also stopped (terminated): M.D. Anderson Cancer Center, Cyclophosphamide + Doxorubicin (NCT03101748)
- 2026-01-22Results posted on the registry: University of Alabama at Birmingham, Combination of Veliparib + Lapatinib (NCT02158507)
- 2025-06-11Also stopped (terminated): M.D. Anderson Cancer Center, Neratinib + Capmatinib (NCT05243641)
- 2025-05-15Results posted on the registry: M.D. Anderson Cancer Center, Neratinib + Capmatinib (NCT05243641)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision